Orthocell Ltd

AU:OCC Australia Biotechnology
Market Cap
$131.03 Million
AU$211.62 Million AUD
Market Cap Rank
#18256 Global
#280 in Australia
Share Price
AU$0.78
Change (1 day)
-0.64%
52-Week Range
AU$0.78 - AU$1.60
All Time High
AU$1.75
Categories
Companies in Australia Biotechnology
About

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more

Orthocell Ltd (OCC) - Net Assets

Latest net assets as of June 2025: AU$14.57 Million AUD

Based on the latest financial reports, Orthocell Ltd (OCC) has net assets worth AU$14.57 Million AUD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$35.24 Million) and total liabilities (AU$20.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$14.57 Million
% of Total Assets 41.35%
Annual Growth Rate 17.41%
5-Year Change -13.66%
10-Year Change 198.26%
Growth Volatility 1452.83

Orthocell Ltd - Net Assets Trend (2010–2025)

This chart illustrates how Orthocell Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Orthocell Ltd (2010–2025)

The table below shows the annual net assets of Orthocell Ltd from 2010 to 2025.

Year Net Assets Change
2025-06-30 AU$14.57 Million +221.43%
2024-06-30 AU$4.53 Million -26.29%
2023-06-30 AU$6.15 Million -37.92%
2022-06-30 AU$9.90 Million -41.30%
2021-06-30 AU$16.87 Million -19.27%
2020-06-30 AU$20.90 Million +94.91%
2019-06-30 AU$10.72 Million +352.09%
2018-06-30 AU$2.37 Million -49.66%
2017-06-30 AU$4.71 Million -3.52%
2016-06-30 AU$4.88 Million +11.42%
2015-06-30 AU$4.38 Million +5653.91%
2014-06-30 AU$76.19K -92.93%
2013-06-30 AU$1.08 Million -31.18%
2011-06-30 AU$1.57 Million +19.36%
2010-06-30 AU$1.31 Million --

Equity Component Analysis

This analysis shows how different components contribute to Orthocell Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 7407040200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$83.49 Million 573.05%
Other Comprehensive Income AU$5.15 Million 35.37%
Total Equity AU$14.57 Million 100.00%

Orthocell Ltd Competitors by Market Cap

The table below lists competitors of Orthocell Ltd ranked by their market capitalization.

Company Market Cap
Zhuhai Sailong Pharmaceutical Co Ltd
SHE:002898
 		$99.73 Million
Shandong Molong Petroleum Machinery Company Limited
PINK:SHANY
 		$99.73 Million
K.P. Energy Limited
NSE:KPEL
 		$99.75 Million
PROQR THERAPEUTICS EO-04
F:0PQ
 		$99.77 Million
Syscom Computer Engineering Co
TW:2453
 		$99.66 Million
MicroPort CardioFlow Medtech Corporation
PINK:MROPF
 		$99.66 Million
X-Legend Entertainment Co Ltd
TW:4994
 		$99.66 Million
icad inc
NASDAQ:ICAD
 		$99.64 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Orthocell Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 4,532,574 to 14,568,834, a change of 10,036,260 (221.4%).
  • Net loss of 8,566,640 reduced equity.
  • Share repurchases of 882,000 reduced equity.
  • Other comprehensive income decreased equity by 2,786,311.
  • Other factors increased equity by 22,271,211.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-8.57 Million -58.8%
Share Repurchases AU$882.00K -6.05%
Other Comprehensive Income AU$-2.79 Million -19.13%
Other Changes AU$22.27 Million +152.87%
Total Change AU$- 221.43%

Book Value vs Market Value Analysis

This analysis compares Orthocell Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 11.95x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 125.97x to 11.95x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2013-06-30 AU$0.01 AU$0.78 x
2014-06-30 AU$0.00 AU$0.78 x
2015-06-30 AU$0.06 AU$0.78 x
2016-06-30 AU$0.06 AU$0.78 x
2017-06-30 AU$0.05 AU$0.78 x
2018-06-30 AU$0.02 AU$0.78 x
2019-06-30 AU$0.09 AU$0.78 x
2020-06-30 AU$0.12 AU$0.78 x
2021-06-30 AU$0.09 AU$0.78 x
2022-06-30 AU$0.05 AU$0.78 x
2023-06-30 AU$0.03 AU$0.78 x
2024-06-30 AU$0.02 AU$0.78 x
2025-06-30 AU$0.07 AU$0.78 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Orthocell Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -58.80%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -113.46%
  • • Asset Turnover: 0.21x
  • • Equity Multiplier: 2.42x
  • Recent ROE (-58.80%) is above the historical average (-348.07%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2013 -618.14% -252.41% 0.30x 8.24x AU$-1.34 Million
2014 -2864.21% -315.62% 0.13x 67.44x AU$-2.19 Million
2015 -85.38% -473.50% 0.12x 1.49x AU$-4.18 Million
2016 -77.49% -567.87% 0.09x 1.46x AU$-4.27 Million
2017 -88.65% -788.46% 0.07x 1.52x AU$-4.65 Million
2018 -242.69% -929.80% 0.12x 2.20x AU$-5.99 Million
2019 -54.57% -618.85% 0.07x 1.27x AU$-6.92 Million
2020 -29.43% -854.88% 0.03x 1.11x AU$-8.24 Million
2021 -53.55% -887.76% 0.05x 1.15x AU$-10.72 Million
2022 -91.94% -594.53% 0.04x 3.83x AU$-10.10 Million
2023 -101.61% -147.26% 0.14x 4.81x AU$-6.86 Million
2024 -158.43% -135.10% 0.20x 5.87x AU$-7.63 Million
2025 -58.80% -113.46% 0.21x 2.42x AU$-10.02 Million

Industry Comparison

This section compares Orthocell Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $31,815,679
  • Average return on equity (ROE) among peers: -60.84%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Orthocell Ltd (OCC) AU$14.57 Million -618.14% 1.42x $99.69 Million
Adalta Ltd (1AD) $2.03 Million -265.03% 1.74x $171.91K
Algorae Pharmaceuticals Ltd (1AI) $2.88 Million -33.65% 0.18x $9.99 Million
ACRUX Ltd (ACR) $17.49 Million -17.99% 0.05x $2.16 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $11.42 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $39.76 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $718.75K
Bio-Gene Technology Ltd (BGT) $4.25 Million -56.43% 0.18x $2.33 Million
BTC Health Ltd (BTC) $11.34 Million -4.81% 0.03x $364.22
Cambium Bio Ltd (CMB) $8.27 Million -79.86% 0.16x $8.11 Million
Clinuvel Pharmaceuticals Ltd (CUV) $240.81 Million 15.02% 0.13x $251.65 Million